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Abstract
Background: Shared decision making is considered an important aspect of chronic disease management. We explored the
feasibility of routinely measuring kidney patients’ involvement in making decisions about renal replacement therapy (RRT) in
National Health Service settings.
Methods: We disseminated a 17-item paper questionnaire on involvement in decision-making among adult patients with
established kidney failurewhomade a decision about RRT in the previous 90 days (Phase 1) and patientswhohad been receiving
RRT for 90–180 days (Phase 2). Recruitment rates were calculated as the ratio between the number of included and expected
eligible patients (I : E ratio). We assessed our sample’s representativeness by comparing demographics between participants
and incident patients in the UK Renal Registry.
Results: Three hundred and five (Phase 1) and 187 (Phase 2) patients were included. For Phase 1, the I : E ratio was 0.44 (range,
0.08–2.80) compared with 0.27 (range, 0.04–1.05) in Phase 2. Study participants were more likely to be white compared with
incident RRT patients (88 versus 77%; P < 0.0001). We found no difference in age, gender or social deprivation. In Phases 1 and 2,
the majority reported a collaborative decision-making style (73 and 69%), and had no decisional conflict (85 and 76%); the
median score for shared decision-making experience was 12.5 (Phase 1) and 10 (Phase 2) out of 20.
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Conclusion: Our study shows the importance of assessing the feasibility of data collection in a chronic disease context prior to
implementation in routine practice. Routine measurement of patient involvement in established kidney disease treatment
decisions is feasible, but there are challenges in selecting the measure needed to capture experience of involvement, reducing
variation in response rate by service and identifyingwhen to capture experience in a servicemanaging people’s chronic disease
over time.
Keywords: chronic kidney disease, doctor–patient communication, implementation, routinemeasure, shared decision-making
Introduction
The National Service Framework for Renal Services (2004) in the
UKadvocates a patient-centred service for all peoplewith chronic
kidney disease (CKD), and promotes partnership in decision-
making [1]. According to the National Institute for Health and
Care Excellence, patients with CKD should be actively engaged
in discussions with the kidney team about available treatment
options, using evidence-based information tailored to their
needs [2–4]. Shared decision-making (SDM) is the process by
which patients and their healthcare professionals deliberate
about available options to choose a course of care that is aligned
with the patient’s preferences. It is dependent on the dialogue
and partnership between patients and health professionals,
and on knowing and understanding the risks and benefits of
available options, while ensuring that the patient’s values are
taken into account [5–7].
Renal services in the UK vary in the format, quality and acces-
sibility of information resources they provide to patients, with
few being able to adequately promote and support SDM [8, 9].
Recent initiatives from the National Health Service (NHS) kidney
and other services to develop patient decision aids (The Dialysis
Decision Aid Booklet; NHS Right Care decision aids) [10], SDM
prompts (The Health Foundation’s MAGIC project: Making Good
decision In Collaboration) [11–14], SDM training for health pro-
fessionals (Advancing Quality Alliance, MAGIC) [11–13] and to
monitor patient involvement in treatment decision-making
(Advancing Quality Alliance, MAGIC, Renal Registries) indicate
that services are progressively evolving towards a more patient-
centred delivery of healthcare. SDM implementation programmes
(Advancing Quality Alliance andMAGIC) suggest that services are
willing to capture patient experiences of treatment decision-
making through the use of questionnaires [14–16]. Furthermore,
NHS England has recently funded an improvement programme
to promote patient-centred coordinated care in the NHS and
measure CKD patients’ activation levels using the Patient Activa-
tion Measure [17, 18].
The feasibility and utility of capturing patients’ experience of
SDM practices in usual care is still unknown. Most measures of
SDM have been designed for discrete decisions in acute illness
contexts (e.g. breast cancer surgery treatments) [7]. It is unclear
if and how suchmeasures can be used in chronic illness contexts
such as CKD [9]. Treatment decisions are often made over mul-
tiple consultations, sometimes spread over months or years,
and the implementation of the decision can be delayed (e.g.
due to a change in disease state) [9]. It is, thus, difficult to identify
the moment at which a definitive treatment decision has been
made and when to survey patients about their involvement in
treatment decision-making.
Therefore, our aims were to assess the feasibility of recruit-
ing CKD patients to measure their involvement in decisions
about renal replacement therapy (RRT) in routine NHS
settings, as well as their ability to access and understand
information.
Materials and methods
In 2013, the NHS Institute for Innovation and Improvement
commissioned the UK Renal Registry to undertake a service
evaluation assessing patient involvement in treatment decision-
making in CKD. The service evaluation consisted of two 3-month
data collection periods. Phase 1 (February–April 2013) included
CKD patients who had made a treatment decision about RRT or
conservative management within the last 90 days. Phase 2
(June–August 2013) focussed on patients who had been receiving
any of these treatments for 90–180 days at the time of recruit-
ment, and had thus recently implemented their treatment deci-
sion (see Box 1). A group of 11 clinical andmethodological experts
in the area of medical decision-making, SDM implementation
and/or CKD were selected to inform the planning and develop-
ment of the service evaluation. They reviewed study materials
as well as iterative drafts of the questionnaire and provided ad-
vice and governance.
Developing the questionnaire
The expert group considered existing instrumentsmeasuring pa-
tient involvement in treatment decision-making [19, 20] and
used the following criteria to select relevant measures; whether
the instrument: (i) had undergone prior validation, (ii) was fit
for use in routine care (i.e. quick and simple to administer), (iii)
was freely available and (v) had been developed for the clinical
context of CKD. The expert group reviewed two iterations of the
provisional questionnaire. It was subsequently piloted with 15
CKD patients recruited at two dialysis centres. They provided
feedback on the wording, clarity, number and order of the
items. Three renal nurses from two centres also reviewed the
questionnaire. We analysed all comments thematically and
made revisions accordingly. The questionnaire was then con-
verted into a format that allowed machine reading of the com-
pleted forms.
The final questionnaire consisted of 4 sections, 17 questions
and included 3 existing scales (see Supplementary data A). Sec-
tion 1 explored patients’ awareness of available treatment
options and information resources. Section 2 focussed on treat-
ment decision making using the following measures:
• The single-item Control Preference Scale assessing patients’
perceived role in the treatment decision [21].
• The 10-item SHAREDmeasure of patients’ experience of SDM
during a consultation.
• The four-item SURE scale to screen for decisional conflict in
clinical settings [22, 23].
Section 3 included demographic items, while Section 4 was to be
completed by the renal nurse only [renal centre name, date of pa-
tient’s first referral to renal centre, patient’s selected treat-
ment and time of treatment start (only for Phase 2)].
Routine measurement of CKD treatment decision-making | 253
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
Eligible renal centres and CKD patients
For Phase 1, we invited 31 renal centres in England who were re-
ceiving funding fromNHS Kidney Care to support secondment of
nursesworking on care planning or SDMprojects. For Phase 2, we
invited all centres that showed interest in participating in Phase 1
(n = 22), as well as all renal centres in Scotland (n = 9). In contrast
to Phase 1, funding from NHS Kidney Care was no longer avail-
able, meaning that participating centres in Phase 2 had to allo-
cate resources for study-related activities within their regular
services.
CKD patients were eligible to take part in the service evalu-
ation if they were 18 years or older. The other inclusion criteria
differed between Phase 1 and Phase 2 (Box 1). Patients who
were not sufficiently proficient in English or lacked the mental
and sensory capacity to read, understand and complete the ques-
tionnaire were excluded. We also checked with renal nurses
whether all criteria were clear and easy to apply in clinical
settings.
Data collection
All eligible renal centres received a PDF version of the question-
naire along with an information pack, a weekly recruitment
sheet and a cover letter for the postal questionnaires. Each centre
was asked to assign a renal nurse in order to identify eligible pa-
tients, as well as to distribute, collect and return the question-
naires to the UK Renal Registry for analysis. These local study
nurses invited eligible patients to complete the questionnaire
in the kidney unit, or sent them a postal version with a cover let-
ter and prepaid envelope.
Data analysis
Recruitment of eligible patients. We assessed the feasibility of
routinely measuring CKD patients’ involvement in selecting a
treatment for their kidney failure. To evaluatewhether renal cen-
tres had been successful in recruiting eligible patients, we calcu-
lated the ratio between the number of included patients and the
expected number of eligible patients (I : E ratio). We determined
the latter based on the quarterly number of incident patients
on RRT, using annual incidence figures derived from themost re-
cent UK Renal Registry report [24]. To assess the degree to which
nurses had recruited a representative sample of kidney patients,
we compared characteristics of study participants with those of
all adult patients starting RRT in participating centres in 2012,
using data from the UK Renal Registry database. For both groups,
we calculated adjusted Indices of Multiple Deprivation (IMD) as a
measure of social deprivation using publicly available IMD data.
We adjusted national values following the method of Payne and
Abel [25] to allow comparison between countries. We performed
χ2 tests to assess differences in gender and ethnicity, and Krus-
kal–Wallis tests for age and IMD.
Aspects of treatment decisionmaking.We undertook descriptive
analyses to summarize all survey responses. To determine a pa-
tient’s decision-making style, we categorized respondents who
reported to have made the decision alone as ‘active’, and those
scoring the health professional havingmade the decision as ‘pas-
sive’. Making the decision together with the health professional
or after considering the health professional’s opinion was seen
as a ‘collaborative’ style. For each of the 10 SHARED items, we as-
signed 2 points for ‘strongly agree’, 1 point for ‘agree’ and no
Box 1. Inclusion criteria for patients in Phase 1 and Phase 2
Phase 1
CKD patients were eligible if they were 18 years or older, and if they fulfilled at least one of the following criteria:
Listed for chronic haemodialysis
• Listed for arteriovenous fistula and not yet on dialysis.
• Started dialysing on a venous catheter within the last 90 days and listed for arteriovenous fistula construction.
• Started dialysing on a venous catheter within the last 90 days and is thought by their medical team to need to continue dialysis
long term (i.e. has definite established renal failure, not acute kidney injury).
Listed for peritoneal dialysis
• Listed for Tenckhoff catheter insertion and not yet on dialysis.
• Started dialysing on a venous catheter within the last 90 days and listed for Tenckhoff catheter insertion.
Listed for kidney transplantation
• Activated on the transplant waiting list within the last 90 days and not yet on dialysis.
• Been given a date for living kidney donor transplantation.
Conservative management
• Opted for conservative management and with an eGFR <10 mL/min/1.73 m2.
Phase 2
CKD patients were eligible if they were 18 years or older and fulfilled at least one of the following criteria:
• Receiving chronic haemodialysis and on RRT for between 90 and 180 days.
• Receiving peritoneal dialysis and on RRT for between 90 and 180 days.
• Received a pre-emptive kidney transplant (i.e. before starting any form of dialysis) between 90 and 180 days ago.
• Opted for conservative management with an eGFR < 10 mL/min/1.73 m2.
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RRT, renal replacement therapy
254 | M.-A. Durand et al.
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points for ‘(strongly) disagree’; the total SHARED score could,
thus, range from 0 to 20 points. Lastly, we categorized respon-
dents reporting ‘no’ to at least one of four SURE items as experi-
encing decisional conflict [22].
Results
Participants
Table 1 shows the characteristics of all participating centres and
patients for both phases. Nineteen and 18 of the 31 invited renal
centres agreed to participate in Phase 1 and Phase 2, respectively.
Ten centres participated in both phases. Of the non-participating
centres, one was already collecting data on patient involvement
in treatment decision making; the remaining centres had com-
peting commitments.
For Phase 1, a total of 385 patients completed the question-
naire, of which 305 fulfilled the inclusion criteria. They were
mostly male (67%), white (92%), with educational attainment at
GSCE or A levels (52%) or no formal qualification (32%), and either
listed for some form of dialysis access procedure (see Box 1) or
had been receiving it for <90 days (77%). The median age was 66
years. For Phase 2, we included 187 of 262 patients who com-
pleted the questionnaire. They were mostly male (62%), white
(83%), with educational attainment at GCSE or A levels (51%) or
no formal qualification (32%), and had a median age of 60 years.
The majority had been receiving haemodialysis for >90 days
(67%). Approximately 5% of questionnaires completed in Phase
1 and 2.5% of questionnaires completed in Phase 2 contained in-
complete information. Incomplete questionnaires were included
in the analysis by using responses to the items that had been
completed.
Recruitment of eligible patients
Table 2 presents the ratio between included and expected eligible
patients (I : E ratio) per centre for both phases. For Phase 1, the
overall I : E ratio was 0.44 (range, 0.08–2.80), indicating that most
centres recruited fewer patients than expected. Almost all cen-
tres returned questionnaires of patients who indeed met the in-
clusion criteria. In Phase 1, one centre (renal centre 4 in Table 2)
had to withdraw 80 responses by patients attending pre-dialysis
education clinics. Theymay have reached a decision on intended
modality, but had not yet come close to implementing it, and
therefore did not meet the inclusion criteria. For Phase 2, the
overall I : E ratio decreased to 0.27 (range, 0.04–1.05). Among the
10 centres contributing to both phases, I : E ratios were signifi-
cantly lower in Phase 2 (P = 0.01). Of the 75 excluded question-
naires received from 15 centres, the majority were removed
from the analysis because patients had been receiving treatment
for <90 or >180 days at the time of recruitment (n = 51).
None of the renal centres systematically returned the weekly
recruitment sheet, thus making it impossible to estimate the
number of invited patients against the number who completed
the questionnaire. Nurses involved in the administration and
collection of questionnaires provided qualitative information
on the ease of data collection. Many reported difficulty in select-
ing appropriate patients in Phase 1. The inclusion criteria were,
thus, simplified in Phase 2.
When comparing characteristics of the complete study sam-
ple (n = 469; excluding duplicates) with those of all adult patients
starting RRT in participating centres in 2012 (n = 2762), we found
no difference in median age in years [64.5 (interquartile range,
IQR, 52.5–75.0) versus 64.4 (IQR, 51.5–74.4); P = 0.5], gender
distribution (65 versus 62% males; P = 0.2) and median-
adjusted IMD [15.2 (IQR, 8.3–29) versus 17.4 (IQR, 9.3–31.5);
P-value, 0.06]. However, patients in our study sample were
more likely to be white compared with the incident RRT popula-
tion (88 versus 79% whites; P< 0.0001).
Options known and discussed with the clinical team
Table 3 reports the results for Phases 1 and 2 (see Box 1 for inclu-
sion and exclusion criteria). In Phase 1, almost all patients (97%)
Table 1. Characteristics of participating renal centres and kidney
patients [values are numbers (valid percentages)a unless indicated
otherwise]
Characteristics Phase 1 Phase 2
Centres
Total number 19 18
Transplant centres 9 8
Median (IQR) number of incident
RRT patients in 2012
104 (71–148) 94 (50–139)
Median (IQR) number of patients
participating in service evaluation
14 (7–25) 10 (3–16)
Patients
Number participating 385 262
Number included in the analysis 305 187
Age, years (median, IQR) 66 (54–77) 60 (48–71)
Gender
Male 204 (67) 116 (62)
Female 99 (33) 71 (38)
Ethnicity
Asian 12 (4) 12 (6)
Black 11 (4) 15 (8)
White 273 (92) 156 (83)
Other 2 (1) 4 (2)
Educational level
No formal qualification 94 (32) 59 (32)
O-level to A-level 154 (52) 94 (51)
Degree or higher 47 (16) 31 (17)
Median (IQR) adjusted IMD 12.8 (7.8–22.8) 18.5 (9.9–38.4)
Time between first referral to dialysis centre and completion of
questionnaire
<90 days 57 (19) n.a.b
90–365 days 63 (21) 58 (31)
>365 days 178 (60) 127 (69)
Selected treatmentc
Listed for chronic haemodialysisd 144 (47) n.a.b
Listed for peritoneal dialysis 91 (30) n.a.b
Listed for kidney transplantation 43 (14) n.a.b
Receiving haemodialysis for >90 days n.a.b 126 (67)
Receiving peritoneal dialysis for
>90 days
n.a.b 31 (17)
Received kidney transplant n.a.b 18 (10)
Conservative managemente 15 (5) 12 (6)
Missingf 37 (12) 0 (0)
IQR, interquartile range; IMD, index of multiple deprivation; n.a., not applicable;
RRT, renal replacement therapy.
aPercentages may not add up to 100% due to rounding, or because patients were
counted twice (see footnote e).
bDid not apply for this phase.
cFor Phase 1, patients listed for both kidney transplantation and some form of
dialysis (n = 13) were counted twice.
dIncluding patients who started on haemodialysis <90 days previously.
ePatients not receiving dialysis or a kidney transplant while having an estimated
glomerular filtration rate <10 mL/min/1.73 m2.
fNo (n = 37) or conflicting (n = 1) information on treatment provided; we considered
being listed for dialysis and having opted for conservative care as conflicting.
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reported being aware of unit-based haemodialysis as a treatment
option; the majority were also aware of peritoneal dialysis (85%),
kidney transplantation (74%) and home-based haemodialysis
(74%) (see Table 3). Fewer than half (46%) knew that conservative
management was a possible treatment option. In Phase 2, most
patients (94%) reported being aware of unit-based haemodialysis,
peritoneal dialysis (73%), kidney transplantation (70%) and
home-based haemodialysis. Only 35% knew that conservative
management was a possible treatment option. For both phases,
Kruskal–Wallis tests revealed that patients who were aware of
conservative management were significantly older than those
who were not (P = 0.005 in Phase 1 and P = 0.002 in Phase 2).
In Phase 1, patients who reported knowing about peritoneal dia-
lysis (P = 0.04), homehaemodialysis (P = 0.03) and transplantation
(P < 0.0001) were significantly younger than patients who were
not aware that those options existed.
After talking to their health professional, the majority of Phase
1 patients perceived unit-based haemodialysis (83%) and periton-
eal dialysis (71%) to be options specifically available to them. This
was less likely for kidney transplantation (49%), home-based
haemodialysis (52%) and conservative management (31%). After
talking to their health professional, most Phase 2 patients per-
ceived unit-based haemodialysis (86%) and peritoneal dialysis
(59%) tobe available to them. Fewer thanhalf felt that kidney trans-
plantation (47%), home-based haemodialysis (35%) and conserva-
tive management (18%) were options available to them. In Phase
1, Kruskal–Wallis tests revealed that patientswhohadbeen offered
peritoneal dialysis (P = 0.04), home haemodialysis (P = 0.0002) and
transplantation (P < 0.0001) tended to be younger. Conversely, pa-
tients who had discussed conservative management with the
clinical team tended to be older (P = 0.0003). In Phase 2, age differ-
ences were only significant for transplantation (P < 0.001) and con-
servative management (P < 0.002).
In Phase 1, patients most frequently reported health profes-
sionals (96%), and leaflets, booklets or DVDs (83%) as sources of
information used beforemaking a treatment decision. Group ses-
sions (36%), websites (28%) and patient decision aids (24%) were
less commonly reported. In Phase 2, patients most frequently re-
ported talking to health professionals (97%), using leaflets, book-
lets or DVDs (80%), and attending group sessions with other
patients (32%). A minority of patients reported using patient de-
cision aids or websites.
Aspects of treatment decision making
Themajority of Phase 1 patients perceived their decisionmaking
style as active (18%) or collaborative (73%), while 6% perceived it
to be passive (see Table 3). In Phase 2, 14% of patients reported a
passive decision making style (i.e. health professionals decided
on their behalf ), with fewer patients reporting an active (16%)
or collaborative style (69%).
With regard to patients’ experience of care consultations, the
median total SHARED score for Phase 1 was 12.5 (IQR, 10–17) out
of 20. The median total SHARED score in Phase 2 was 10 (IQR,
8–14) out of 20. Furthermore, Kruskal–Wallis test revealed that in
Phase 1, patients who had used a decision aid (24.2%) tended to
score higher on SHARED than patients who had used other
sources of information and support (P = 0.025). Therewere no stat-
istically significantdifferences inSHARED total scores according to
gender, age, ethnicity, education or treatment modality.
Table 2. Number of completed questionnaires, and the ratio between the included and expected number of included patients per centre
Renal
centre
Eligible patients
expected (E)a
Phase 1 Phase 2
Completed
questionnaires
Eligible patients
included (I)
I : E
ratio
Completed
questionnaires
Eligible patients
included (I)
I : E
ratio
1 34 18 18 0.53 30 17 0.50
2 37 16 16 0.43 16 12 0.32
3 7 9 9 1.24 6 5 0.69
4 19 105 25 1.35 17 14 0.76
5 66 14 14 0.21 23 18 0.27
6 31 6 6 0.19 8 3 0.10
7 23 8 8 0.35 1 1 0.04
8 19 10 10 0.54 7 6 0.32
9 43 18 18 0.42 22 15 0.35
10 13 7 7 0.53 9 5 0.38
11 18 10 10 0.56
12 31 25 25 0.81
13 28 5 5 0.18
14 26 39 39 1.50
15 19 16 16 0.85
16 40 3 3 0.08
17 61 35 35 0.58
18 13 35 35 2.80
19 13 6 6 0.48
20 5 3 2 0.42
21 19 25 20 1.05
24 3 2 2 0.62
25 10 13 8 0.80
26 28 14 14 0.51
27 25 15 13 0.53
Overall 698 385 305 0.44 262 187 0.27
aBased on the quarterly number of incident patients on RRT in 2012.
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Scores on the SURE test revealed that the majority of patients
(85%) in Phase 1 answered yes to all SURE items, thus indicating
the absence of decisional conflict. In Phase 2, 76% of patients
were devoid of decisional conflict, while 24% indicated some
level of decisional conflict. Kruskal–Wallis test revealed that
Phase 1 patients who had used a decision aid (24.2%) tended
to score higher on SURE, showing less decisional conflict
than those who had been provided with alternative sources of
information (P = 0.003). Therewere no statistically significant differ-
ences in SURE scores according to gender, age, ethnicity, education
or treatment modality.
Discussion
This service evaluation assessed the feasibility of routine meas-
urement of patient involvement in treatment decision making
within the complex clinical context of CKD. When compared
with annual incidence figures, the recruitment rates (as shown
by the I : E ratios) were lower than expected. Despite simplifying
Phase 2 inclusion criteria, recruitment rates remained lower
than expected. A sizeable proportion of completed question-
naires did notmeet the inclusion criteria andwere thus excluded
from the analysis. Study participantsweremore likely to bewhite
compared with incident RRT patients. Most participants generally
knewand discussed four treatment optionswith their healthcare
professionals: unit-based haemodialysis, peritoneal dialysis,
transplantation and home-based haemodialysis. A minority of
participants knew of, and were offered, conservative manage-
ment. Age was a significant predictor of the options known and
discussed. About 70% of patients across both phases reported a
collaborative role in decision making (Control Preference Scale).
The median SHARED score was 12.5 (Phase 1) and 10 (Phase 2)
out of 20. The majority of participants were devoid of decisional
conflict (SURE score).
The strengths of this service evaluation were the pragmatic
recruitment of patients across 27 renal units in NHS routine set-
tings, and the involvement of a dedicated multidisciplinary ex-
pert group. However, several limitations need to be considered.
First, this work was funded as part of a time-limited ‘Call to Ac-
tion’ sponsored by the NHS Institute for Innovation and Improve-
ment, in which the measurement of patient experience of
treatment decision making was intended to serve both as a dis-
ruptive innovation and provide a tension for change. These
time constraints have affected the design of this evaluation and
our ability to thoroughly set up the service evaluation, and
hindered the optimal recruitment of renal centres and nurses.
Second, contextual factors may have influenced patient re-
sponses. In Phase 1, NHS Kidney Care funding and SDM pro-
grammes conducted in parallel to this service evaluation may
have affected data collection. In Phase 2, Scottish centres who
had not been involved in Phase 1 took part in the service evalu-
ation. Third, our decision to recruit new patients in Phase 2, as
opposed to collecting data at two different time points in the
same patient cohort, may be considered a weakness of this pro-
ject. Using the same cohort would have eliminated any potential
influence of case-mix or unit-level factors on the survey re-
sponses, andwould have enabled us to confidently assign the dif-
ferences in responses to the timing of the questionnaire. However,
this was rendered impossible by the timescales of the service
evaluation. In addition, most questionnaires were handed out by
the renal nurses and completed at the time of (or close to) the con-
sultation. It is possible that the data being captured by the same
professionals as those providing care may have led to response
biases (e.g. social acceptability) and ceiling effects, commonly
seen in SDM questionnaires used in similar contexts [26]. Finally,
given that none of the renal centres systematically returned the
weekly recruitment sheet, we are unable to estimate the number
of invitedpatientsagainst thosewho completed thequestionnaire.
Measuring patient involvement in the context of chronic ill-
nesses, and specifically CKD, is possible in routine NHS settings
but presents challenges. Establishing routine data collection ap-
peared more complex and time-consuming than expected, and
Table 3. Survey responses regarding treatment awareness and
decision making for Phases 1 and 2 [values are numbers
(percentages)a unless indicated otherwise]
Questionnaire item
Phase 1
(N = 305)
Phase 2
(N = 187)
Patients’ awareness of treatment options
Available in general
Unit-based haemodialysis 293 (97) 176 (94)
Home-based haemodialysis 223 (74) 114 (61)
Peritoneal dialysis 257 (85) 136 (73)
Conservative management 138 (46) 66 (35)
Kidney transplantation 224 (74) 130 (70)
Missing 2 (1) None
Perceived availability after talking to caregiver
Unit-based haemodialysis 251 (83) 161 (86)
Home-based haemodialysis 158 (52) 66 (35)
Peritoneal dialysis 215 (71) 111 (59)
Conservative management 95 (31) 33 (18)
Kidney transplantation 148 (49) 88 (47)
Missing 2 (1) 1 (1)
Information sources provided by the centre
Health professionals 289 (96) 180 (97)
Group sessions with other
patients
108 (36) 60 (32)
Leaflet, booklet or DVD 251 (83) 149 (80)
Website with general
information
84 (28) 35 (19)
Patient decision aid 73 (24) 26 (14)
Missing 3 (1) 1 (1)
Aspects of the treatment decision making
Patients’ perceived decision-making style (CPS)
Active 54 (18) 29 (16)
Collaborative 222 (73) 129 (69)
Passive 18 (6) 27 (14)
Missing 11 (4) 2 (1)
Decision-making process (SHARED)
Total score (median, IQR) 12.5 (10–17) 10 (8–14)
Staff input (median, IQR)b 4 (4–7) 4 (3–5)
Patient input (median, IQR)c 3.5 (3–6) 3 (2–5)
Shared decision (median, IQR)d 4 (3–6) 3 (2–4)
Missing ≥1 SHARED item 51 (17) 19 (10)
Answering ‘not sure’ to ≥1
SHARED item
n.a.e 91 (49)
SURE score
Yes 242 (85) 139 (76)
No 43 (15) 44 (24)
Missing ≥1 SURE item 20 (7) 4 (2)
Currently on treatment initially
chosen
n.a. 160 (87)
CPS, Control Preference Scale; IQR, interquartile range; n.a., not applicable.
aPercentages may not add up to 100% due to rounding.
bItems 1–4 of the SHARED scale with maximum score of 8.
cItems 5–7 of the SHARED scale with maximum score of 6.
dItems 8–10 of the SHARED scale with maximum score of 6.
e‘Not sure’ was only available as an answering option in Phase 2.
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required significant resources and commitment from the entire
renal team at each site. Questionnaire timing was also a signifi-
cant challenge of this project. Iterative adjustments were re-
quired to both the content of the questionnaire, processes of
data collection and supporting documents for nurses and other
members of the renal team involved in recruitment. In the future,
routine data collection of patient involvement in CKD treatment
could be facilitated by integrating selected SDM items in patient-
reported outcome measures (PROMs) and experience measures
(PREMs) routinely collected in renal registries in Europe [16].
Some of the challenges associated with the routine data collec-
tion of PROMs and PREMs data are comparable to those we en-
countered in this service evaluation [16].
While evidence shows that conservative management is ac-
cepted across UK renal units [27], our findings suggest that over
half of patients facing RRT treatment decisions are not aware of
conservative management as a possible treatment option, and
do not tend to discuss this treatment with their health profes-
sionals. Given the limitations associated with the completion of
questionnaires in renal units, with renal nurses, it is difficult to
draw firm conclusions about the aspects of treatment decision
making in our sample. Further investigation is required.
This service evaluation confirms the importance of assessing
the feasibility of routine data collection in complex clinical and
decision-making contexts, allowing sufficient set-up time and
dedicated resources, before attempting to implement systematic
data collection procedures. The study findings are relevant in the
context of a National UK programme, recently funded by NHS
England, which seeks to improve health-related patient activa-
tion in the context of CKD [17, 18]. The present study may, thus,
inform some of the data collection procedures (e.g. timing and
deployment of the patient activation measure questionnaire),
systems and resources required to reliably and sustainably col-
lect information about patient activation across theNHS and pro-
mote patient-centred coordinated care.
Supplementary data
Supplementary data are available online at http://ckj.oxford
journals.org.
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